Moreover, studies on melanoma cells showed that treatment with the hypomethylating agent 5-azacytidine can orchestrate transcriptional derepression in hypermethylated PD-L1 tumors, leading to amplification of PD-L1 expression [194]. Here, CD274 is linked to melanoma.